Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 91 clinical trials
featured
GUIDE-IT - GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) -The goal of this US prospective outpatient AF registry is to identify real world treatment patterns in patients with AF(atrial fibrillation), outside of randomized controlled trials. Specifically, the registry will attempt to define current treatment patterns and their relationship with outcomes, including stroke, all-cause mortality, and quality-of-life.

GUIDE-IT - GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) -The goal of this US prospective outpatient AF registry is to identify real world treatment patterns in patients with AF(atrial fibrillation), outside of randomized controlled trials. Specifically, the registry will attempt to define current treatment patterns …

  • 128 views
  • 25 Mar, 2021
  • 2 locations
Survival Study of the Recombinant Human Neuregulin-1 in Subjects With Chronic Heart Failure.

The purpose of this study is to evaluate efficacy of rhNRG-1 in reducing the death rate of heart failure subjects with baseline NT-proBNP level between 600 pg/ml and 1700 pg/mL and NYHA class II

ejection fraction
systolic heart failure
nt-probnp
  • 39 views
  • 01 May, 2021
  • 94 locations
Changes in NT-proBNP and Outcomes Safety and Tolerability in HFpEF Patients With Acute Decompensated Heart Failure (ADHF) Who Have Been Stabilized During Hospitalization and Initiated In-hospital or Within 30 Days Post-discharge (PARAGLIDE-HF)

The purpose of this study is to assess the effect of sacubitril/valsartan (LCZ696) vs. valsartan on changes in NT-proBNP and outcomes, safety and tolerability in patients with HFpEF (left

  • 27 views
  • 01 Apr, 2021
  • 84 locations
Effect Levosimendan Administration on Postoperative NT-proBNP in Cardiac Risk Patients

This is a prospective randomised trial investigating the effect of a preemptive administration of levosimendan on postoperative cardiac NT-proBNP concentrations.

  • 0 views
  • 29 Jan, 2021
  • 1 location
A Study of Mavacamten in Participants With HFpEF and Chronic Elevation of cTnI and/or NT-proBNP

ejection fraction (HFpEF) and chronic elevation of cTnI and/or NT-proBNP. Data from this study will inform future study designs of mavacamten in participants with HFpEF.

  • 0 views
  • 01 May, 2021
  • 13 locations
Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure

A multi-center, randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the effect of injectable Neucardin on the heart function in male patients with NT-proBNP 1700

  • 0 views
  • 03 Feb, 2021
  • 2 locations
A Study to Assess the Safety Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction

to evaluate the effect of IONIS-AGT-LRx weekly SC injection on plasma AGT concentration and N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) levels at each scheduled visit in chronic

  • 0 views
  • 16 May, 2021
  • 2 locations
Effect of the MobiusHD in Patients With Heart Failure

This is a prospective, multi-center, open-label clinical trial intended to evaluate the safety and effectiveness of the MobiusHD in patients with heart failure and reduced ejection fraction.

  • 0 views
  • 15 Feb, 2021
  • 5 locations
Phase 2 Study to Assess Safety Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH

This is a multi-center, randomized, double-blind, controlled, Phase 2 study to assess the safety, tolerability, and efficacy of pemziviptadil (PB1046) at the optimally titrated dose after 16 weeks of treatment. Subjects will be randomized in a 2:1 ratio to one of two parallel dose groups: a) high-dose group where PB1046 …

heart disease
hypertension
body mass index
immunodeficiency
forced expiratory volume
  • 29 views
  • 05 May, 2021
  • 26 locations
Left Bundle Branch Pacing Versus Biventricular Pacing for Cardiac Resynchronization Therapy

The present study will recruit 40 symptomatic heart failure patients with left ventricular ejection fraction (LVEF) below 35% and complete left bundle branch block(QRSd130 ms). Each patient was randomized to either left bundle branch pacing(LBBP) or biventricular pacing(BivP) and was followed up for at least 6 months. The objective is …

ejection fraction
cardiac resynchronization therapy
  • 0 views
  • 26 Jan, 2021
  • 1 location